PRCWF (Sofgen Pharma) Long-Term Debt: $41.41 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRCWF Sofgen Pharma SA PRCWF
24 GF Score
Price $0.00
! 4 Warning Signs
View Full Analysis

What is Sofgen Pharma Long-Term Debt?

Sofgen Pharma PRCWF 24 Long-Term Debt is $41.41 Mil as of Dec. 2024. GuruFocus rates PRCWF with a GF Score™ of 24/100. The stock has 4 warning signs investors should review.

Sofgen Pharma's Long-Term Debt for the quarter that ended in Dec. 2024 was $41.41 Mil.

Sofgen Pharma's quarterly Long-Term Debt declined from Sep. 2023 ($220.68 Mil) to Dec. 2023 ($31.11 Mil) but then increased from Dec. 2023 ($31.11 Mil) to Dec. 2024 ($41.41 Mil).

Sofgen Pharma's annual Long-Term Debt increased from Dec. 2022 ($29.17 Mil) to Dec. 2023 ($31.11 Mil) and increased from Dec. 2023 ($31.11 Mil) to Dec. 2024 ($41.41 Mil).

Sofgen Pharma  (OTCPK:PRCWF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sofgen Pharma Long-Term Debt Related Terms

Sofgen Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sofgen Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sofgen Pharma Long-Term Debt Chart

Sofgen Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial 339.74 29.04 29.17 31.11 41.41

Sofgen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Dec24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 150.01 169.64 220.68 31.11 41.41
PRCWF
24GF Score
Sofgen Pharma SA PRCWF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $41.41 Mil mean?
Sofgen Pharma (PRCWF) has a Long-Term Debt of $41.41 Mil as of Dec. 2024.
Is Sofgen Pharma's Long-Term Debt too high?
Sofgen Pharma's current Long-Term Debt is $41.41 Mil. Overall, Sofgen Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sofgen Pharma's Long-Term Debt compare to BKUH and ORGO?
Sofgen Pharma's Long-Term Debt of $41.41 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sofgen Pharma's current Long-Term Debt is $41.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sofgen Pharma stock overvalued right now?
Sofgen Pharma (PRCWF) has a current Long-Term Debt of $41.41 Mil. The current Long-Term Debt is $41.41 Mil. Sofgen Pharma's overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sofgen Pharma (PRCWF), the current Long-Term Debt is $41.41 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sofgen Pharma Business Description

Address 9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is an integrated healthcare and pharmaceutical company that develops and manufactures pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The company's segment includes NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. It generates maximum revenue from the NextGel segment. It has geographic presence in Bolivia, Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, and the United States.
24GF Score

Get the complete analysis for PRCWF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price